A major limitation to available data is that the optimum levels of control for particular patients are not identified as there are individual differences in the risks of hypo- glycemia, weight gain, and other adverse effects. Furthe with multifactorial interventions, it is unclear how differ ent components (., educational interventions, glycem targets, food selection, lifestyle changes, and medication contribute to the reduction of complications. The level o evidence for a given guideline should be considered wh individualizing targets. Intensification of treatment over time is essential for people with type 2 diabetes so that they continue to mee therapeutic goals. It should be made clear that progress toward treatment targets.
